concentration of formulation market share;

(c) if so, what definition of high concentration of formulation market share has been taken;

(d) whether it is -a fact that another drug Metranidazole for same indication have a better spread of formulations but still the same have been covered under price control whereas Tinidazole exempted from price control;

(e) what are the reasons and which of the exclusion criteria is satisfied by Tini dazole; and

(f.) what steps have been taken to review the arbitrary exclusion of Tinidazole by Kelkar Committee ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL) : (a) Sales turnover of formulations is not monitored" by this Ministry.

(h) and (c) The Kelkar Committee had also taken into account 'high concentration of formulation market share' while adopting exclusion criteria laid down by the Committee for inclusion of drugs under price control.

(d) to (f) Th© Kelkar Committee in its supplementary report had recommended for retention of Metronidazole under price control due to very high concentration of formulation market by two companies whereas there was no consensus in caise of Tinidazole for including this drug under price control.

**Prices of formulations**

1475. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be plea-sed to refer to the answer to Unstarred Question 1594 given in the Rajya Sabha on the 8th May, 1989 and state;

(a) whether it is a fact that Sulphamoxole. Hydroprogesterone, Glipizide and Glybenclamide were all price controlled under DPCO, 1979; 529 RS—6.

(b) if so, what were the last prices fixed in respect to each of these drugs Under the said order;

(c) what w«re the last prices fixed for each formulations based on each drug under DPCO, 1979.

(d) whether it is a fact that no revision was possible under DPCO, 1987 without furnishing details in Form 2A;

(e) when and what are the prices furnished for these drugs under DPCO, 1987;

(f) what is the present price of each of these bulk drugs and formulations based on each;

(g) whether it is a fact that the turn=-over of each of these drugs' is more than Rupees fifty lacs per annum; and

(h) if so, on what basis these drugs have been price decontrolled?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTRY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) All drugs referred to in the question except Hydroprogesterone were price controlled under DPCO, 1979.

(h) , (c). (e) and (f) The required details to the extent possible will be collected and laid on the Table of the House.

(d) Yes, Sir.

(g) Sales turnover is not monitored.

(h) Out of the above three drugs, it has been decided to include Sulphamoxole under price controlled category as per the recommendations contained in the Supplementary Report of the Kelkar Commiitee.

**Communication of the assessed amounts due from drug companies**

1476. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1607 given in the Rajya Sabha on the 8th May, 1989 and state: